Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% Higher - What's Next?

robot
Abstract generation in progress

Zenas BioPharma (NASDAQ:ZBIO) saw its stock price rise by 13.8% during trading, closing at $26.48 with reduced trading volume. Analysts have issued new price targets for ZBIO, with a consensus “Moderate Buy” rating and an average price target of $43.14. Insider transactions show CEO Leon O. Moulder, Jr. recently increased his stake in the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)